Predictors of secukinumab treatment response and continuation in axial spondyloarthritis
Marion Pons, Stylianos Georgiadis, Merete Lund Hetland, Z. Faizy Ahmadzay et autres
Objective: In patients with axial spondyloarthritis (axSpA) initiating secukinumab, we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis …
dk, se, cz, si (code pays fourni par la source)
0 citations
DiRROS repository (University of Maribor)